# A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)

> **NCT02941991** · — · COMPLETED · sponsor: **Astellas Institute for Regenerative Medicine** · enrollment: 12 (actual)

## Conditions studied

- Stargardt's Macular Dystrophy

## Interventions

- **BIOLOGICAL:** hESC-RPE

## Key facts

- **NCT ID:** NCT02941991
- **Lead sponsor:** Astellas Institute for Regenerative Medicine
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-16
- **Primary completion:** 2019-10-02
- **Final completion:** 2019-10-02
- **Target enrollment:** 12 (ACTUAL)
- **Last updated:** 2020-12-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02941991

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02941991, "A Follow up Study to Determine the Safety and Tolerability of Sub-retinal Transplantation of Human Embryonic Stem Cell Derived Retinal Pigmented Epithelial (hESC-RPE) Cells in Patients With Stargardt's Macular Dystrophy (SMD)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02941991. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*